Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01617954

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score — PROMIS  

Hormone Receptor Positive Malignant Neoplasm of Breast Clinical Trial

Official title:
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Clinical Trial Summary

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Clinical Trial Description

The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01617954
Study type Observational
Source Agendia
Contact
Status Completed
Phase N/A
Start date May 2012
Completion date December 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03165487 - Comparison of the Breast Tumor Microenvironment
Completed NCT03088527 - Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer Phase 1
Completed NCT02347449 - The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population N/A
Withdrawn NCT04088032 - Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer Early Phase 1
Completed NCT04483505 - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Phase 1
Not yet recruiting NCT04088110 - Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Phase 2
Completed NCT01589367 - Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Phase 2
Active, not recruiting NCT02109913 - Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane N/A
Active, not recruiting NCT02668666 - Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Not yet recruiting NCT03910712 - Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC Phase 2
Recruiting NCT04030507 - Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer N/A
Completed NCT03969121 - Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer Phase 3
Recruiting NCT06120283 - BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Phase 1
Completed NCT02248571 - Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Phase 4
Completed NCT03594578 - Prospective Thinking in Hormone-Responsive Breast Cancer N/A
Recruiting NCT06253195 - BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Phase 1
Not yet recruiting NCT02025712 - Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer Phase 2